Company news
Atrium Therapeutics, Inc. (NASDAQ:RNA) news
Atrium Therapeutics, Inc. news releases on 6ix. Latest, Sep 2, 2026: Atrium Therapeutics to Participate in Upcoming Investor Conferences
Press releases & updates
Atrium Therapeutics to Participate in Upcoming Investor Conferences
September 2, 2026
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
August 13, 2026
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
July 14, 2026
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026
Atrium Therapeutics Reports First Quarter 2026 Financial Results
May 14, 2026
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
April 23, 2026
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2026
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
February 27, 2026
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
February 27, 2026
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 26, 2026
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
February 23, 2026
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
February 18, 2026
Avidity Biosciences Announces Expected Record Date for Spin-Off
February 1, 2026
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
November 18, 2025
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
November 9, 2025
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
October 25, 2025
Avidity Biosciences to Participate in Upcoming Investor Conference
October 15, 2025
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
October 12, 2025
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
October 5, 2025
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
September 10, 2025
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44
September 9, 2025
Avidity Biosciences Announces Proposed Public Offering of Common Stock
September 9, 2025
Avidity Biosciences to Participate in Upcoming Investor Conferences
August 26, 2025
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights
August 6, 2025
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
July 27, 2025
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
July 22, 2025
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
June 10, 2025
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
June 8, 2025
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
June 8, 2025
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2025
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
May 7, 2025
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
April 7, 2025
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
March 30, 2025
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
March 17, 2025
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skippi...
March 16, 2025
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 11, 2025
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
February 27, 2025
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights
February 26, 2025
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
January 7, 2025
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
November 11, 2024
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
November 6, 2024
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
October 30, 2024
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy
October 29, 2024
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
October 2, 2024
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
September 4, 2024
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
August 18, 2024
Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
August 8, 2024
Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skippin...
August 8, 2024
Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
August 4, 2024
Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
June 19, 2024